nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—TLR4—chronic obstructive pulmonary disease	0.521	0.889	CbGaD
Naloxone—ALB—chronic obstructive pulmonary disease	0.0651	0.111	CbGaD
Naloxone—SLCO1A2—Prednisolone—chronic obstructive pulmonary disease	0.0447	0.187	CbGbCtD
Naloxone—SLCO1A2—Prednisone—chronic obstructive pulmonary disease	0.0422	0.177	CbGbCtD
Naloxone—CYP2C8—Montelukast—chronic obstructive pulmonary disease	0.0304	0.127	CbGbCtD
Naloxone—ALB—Prednisone—chronic obstructive pulmonary disease	0.0218	0.0913	CbGbCtD
Naloxone—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0215	0.0899	CbGbCtD
Naloxone—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0145	0.0607	CbGbCtD
Naloxone—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0138	0.0579	CbGbCtD
Naloxone—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0123	0.0516	CbGbCtD
Naloxone—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.0121	0.0506	CbGbCtD
Naloxone—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.0114	0.0478	CbGbCtD
Naloxone—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00724	0.0303	CbGbCtD
Naloxone—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00684	0.0286	CbGbCtD
Naloxone—Cardiac fibrillation—Salbutamol—chronic obstructive pulmonary disease	0.00316	0.044	CcSEcCtD
Naloxone—Excitement—Aminophylline—chronic obstructive pulmonary disease	0.00234	0.0326	CcSEcCtD
Naloxone—Abdominal cramps—Aminophylline—chronic obstructive pulmonary disease	0.0017	0.0237	CcSEcCtD
Naloxone—Excitement—Salbutamol—chronic obstructive pulmonary disease	0.00168	0.0234	CcSEcCtD
Naloxone—Drug dependence—Prednisone—chronic obstructive pulmonary disease	0.00124	0.0172	CcSEcCtD
Naloxone—Ventricular tachycardia—Tiotropium—chronic obstructive pulmonary disease	0.00108	0.0151	CcSEcCtD
Naloxone—Rhinorrhoea—Montelukast—chronic obstructive pulmonary disease	0.00106	0.0147	CcSEcCtD
Naloxone—Coma—Aminophylline—chronic obstructive pulmonary disease	0.00105	0.0146	CcSEcCtD
Naloxone—Depression—Roflumilast—chronic obstructive pulmonary disease	0.00096	0.0134	CcSEcCtD
Naloxone—Withdrawal syndrome—Prednisone—chronic obstructive pulmonary disease	0.000823	0.0115	CcSEcCtD
Naloxone—TLR4—lung—chronic obstructive pulmonary disease	0.000811	0.17	CbGeAlD
Naloxone—Cardiac disorder—Roflumilast—chronic obstructive pulmonary disease	0.000802	0.0112	CcSEcCtD
Naloxone—Irritability—Aminophylline—chronic obstructive pulmonary disease	0.000795	0.0111	CcSEcCtD
Naloxone—Mediastinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.000779	0.0108	CcSEcCtD
Naloxone—Mental disorder—Roflumilast—chronic obstructive pulmonary disease	0.000757	0.0105	CcSEcCtD
Naloxone—Hyperkinesia—Montelukast—chronic obstructive pulmonary disease	0.000746	0.0104	CcSEcCtD
Naloxone—Tension—Roflumilast—chronic obstructive pulmonary disease	0.000738	0.0103	CcSEcCtD
Naloxone—Pulmonary oedema—Salbutamol—chronic obstructive pulmonary disease	0.000734	0.0102	CcSEcCtD
Naloxone—Nervousness—Roflumilast—chronic obstructive pulmonary disease	0.00073	0.0102	CcSEcCtD
Naloxone—Hyperkinesia—Salbutamol—chronic obstructive pulmonary disease	0.000719	0.01	CcSEcCtD
Naloxone—Tremor—Roflumilast—chronic obstructive pulmonary disease	0.000705	0.00981	CcSEcCtD
Naloxone—CREB1—respiratory system—chronic obstructive pulmonary disease	0.000672	0.141	CbGeAlD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Roflumilast—chronic obstructive pulmonary disease	0.000636	0.00885	CcSEcCtD
Naloxone—Nervous system disorder—Roflumilast—chronic obstructive pulmonary disease	0.000602	0.00838	CcSEcCtD
Naloxone—Skin disorder—Roflumilast—chronic obstructive pulmonary disease	0.000596	0.0083	CcSEcCtD
Naloxone—Irritability—Montelukast—chronic obstructive pulmonary disease	0.000593	0.00825	CcSEcCtD
Naloxone—CREB1—connective tissue—chronic obstructive pulmonary disease	0.000592	0.124	CbGeAlD
Naloxone—Irritability—Salbutamol—chronic obstructive pulmonary disease	0.000571	0.00795	CcSEcCtD
Naloxone—Nasopharyngitis—Arformoterol—chronic obstructive pulmonary disease	0.000567	0.00789	CcSEcCtD
Naloxone—Nasopharyngitis—Formoterol—chronic obstructive pulmonary disease	0.000567	0.00789	CcSEcCtD
Naloxone—Nasopharyngitis—Montelukast—chronic obstructive pulmonary disease	0.000555	0.00773	CcSEcCtD
Naloxone—CREB1—bronchus—chronic obstructive pulmonary disease	0.000553	0.116	CbGeAlD
Naloxone—CREB1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000541	0.113	CbGeAlD
Naloxone—Nasopharyngitis—Salbutamol—chronic obstructive pulmonary disease	0.000535	0.00745	CcSEcCtD
Naloxone—Flushing—Aminophylline—chronic obstructive pulmonary disease	0.000535	0.00744	CcSEcCtD
Naloxone—Gastrointestinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.00053	0.00738	CcSEcCtD
Naloxone—Angiopathy—Tiotropium—chronic obstructive pulmonary disease	0.000493	0.00686	CcSEcCtD
Naloxone—Tension—Aminophylline—chronic obstructive pulmonary disease	0.000492	0.00685	CcSEcCtD
Naloxone—Mediastinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00049	0.00682	CcSEcCtD
Naloxone—Nervousness—Aminophylline—chronic obstructive pulmonary disease	0.000487	0.00678	CcSEcCtD
Naloxone—Abdominal pain—Roflumilast—chronic obstructive pulmonary disease	0.000485	0.00676	CcSEcCtD
Naloxone—Mental disorder—Tiotropium—chronic obstructive pulmonary disease	0.000476	0.00663	CcSEcCtD
Naloxone—Tremor—Aminophylline—chronic obstructive pulmonary disease	0.00047	0.00654	CcSEcCtD
Naloxone—Agitation—Aminophylline—chronic obstructive pulmonary disease	0.000461	0.00642	CcSEcCtD
Naloxone—Sweating—Salbutamol—chronic obstructive pulmonary disease	0.000442	0.00616	CcSEcCtD
Naloxone—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.00044	0.00613	CcSEcCtD
Naloxone—Convulsion—Aminophylline—chronic obstructive pulmonary disease	0.000435	0.00605	CcSEcCtD
Naloxone—Hallucination—Montelukast—chronic obstructive pulmonary disease	0.000427	0.00595	CcSEcCtD
Naloxone—Pulmonary oedema—Prednisolone—chronic obstructive pulmonary disease	0.000421	0.00586	CcSEcCtD
Naloxone—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.00042	0.00585	CcSEcCtD
Naloxone—Hypertension—Tiotropium—chronic obstructive pulmonary disease	0.000408	0.00569	CcSEcCtD
Naloxone—Cardiac disorder—Arformoterol—chronic obstructive pulmonary disease	0.000407	0.00567	CcSEcCtD
Naloxone—Cardiac disorder—Formoterol—chronic obstructive pulmonary disease	0.000407	0.00567	CcSEcCtD
Naloxone—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.000401	0.00559	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.0004	0.00557	CcSEcCtD
Naloxone—Tachycardia—Aminophylline—chronic obstructive pulmonary disease	0.0004	0.00556	CcSEcCtD
Naloxone—Cardiac disorder—Montelukast—chronic obstructive pulmonary disease	0.000399	0.00555	CcSEcCtD
Naloxone—Mediastinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000395	0.0055	CcSEcCtD
Naloxone—Mediastinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000395	0.0055	CcSEcCtD
Naloxone—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.00039	0.00543	CcSEcCtD
Naloxone—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000387	0.00539	CcSEcCtD
Naloxone—Cardiac disorder—Salbutamol—chronic obstructive pulmonary disease	0.000384	0.00535	CcSEcCtD
Naloxone—Flushing—Salbutamol—chronic obstructive pulmonary disease	0.000384	0.00535	CcSEcCtD
Naloxone—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	0.000384	0.00535	CcSEcCtD
Naloxone—Mental disorder—Formoterol—chronic obstructive pulmonary disease	0.000384	0.00535	CcSEcCtD
Naloxone—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.000379	0.00527	CcSEcCtD
Naloxone—Tachycardia—Tiotropium—chronic obstructive pulmonary disease	0.000377	0.00525	CcSEcCtD
Naloxone—Mental disorder—Montelukast—chronic obstructive pulmonary disease	0.000376	0.00524	CcSEcCtD
Naloxone—Angiopathy—Salbutamol—chronic obstructive pulmonary disease	0.000376	0.00523	CcSEcCtD
Naloxone—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000375	0.00522	CcSEcCtD
Naloxone—Tension—Formoterol—chronic obstructive pulmonary disease	0.000375	0.00522	CcSEcCtD
Naloxone—Tension—Arformoterol—chronic obstructive pulmonary disease	0.000375	0.00522	CcSEcCtD
Naloxone—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000373	0.0052	CcSEcCtD
Naloxone—Chills—Salbutamol—chronic obstructive pulmonary disease	0.000372	0.00517	CcSEcCtD
Naloxone—Nervousness—Arformoterol—chronic obstructive pulmonary disease	0.000371	0.00516	CcSEcCtD
Naloxone—Nervousness—Formoterol—chronic obstructive pulmonary disease	0.000371	0.00516	CcSEcCtD
Naloxone—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000365	0.00508	CcSEcCtD
Naloxone—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.000363	0.00505	CcSEcCtD
Naloxone—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.000358	0.00498	CcSEcCtD
Naloxone—Tremor—Formoterol—chronic obstructive pulmonary disease	0.000358	0.00498	CcSEcCtD
Naloxone—CREB1—lung—chronic obstructive pulmonary disease	0.000357	0.0747	CbGeAlD
Naloxone—Tension—Salbutamol—chronic obstructive pulmonary disease	0.000354	0.00492	CcSEcCtD
Naloxone—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.000351	0.00488	CcSEcCtD
Naloxone—Agitation—Formoterol—chronic obstructive pulmonary disease	0.000351	0.00488	CcSEcCtD
Naloxone—Tremor—Montelukast—chronic obstructive pulmonary disease	0.00035	0.00488	CcSEcCtD
Naloxone—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.00035	0.00487	CcSEcCtD
Naloxone—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000347	0.00483	CcSEcCtD
Naloxone—Agitation—Montelukast—chronic obstructive pulmonary disease	0.000344	0.00478	CcSEcCtD
Naloxone—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000338	0.0047	CcSEcCtD
Naloxone—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000333	0.00464	CcSEcCtD
Naloxone—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000331	0.00461	CcSEcCtD
Naloxone—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.00033	0.00459	CcSEcCtD
Naloxone—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.00033	0.00459	CcSEcCtD
Naloxone—Cardiac arrest—Prednisolone—chronic obstructive pulmonary disease	0.000326	0.00454	CcSEcCtD
Naloxone—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000324	0.00451	CcSEcCtD
Naloxone—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000324	0.00451	CcSEcCtD
Naloxone—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000324	0.00451	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000323	0.00449	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000323	0.00449	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000316	0.0044	CcSEcCtD
Naloxone—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000311	0.00433	CcSEcCtD
Naloxone—Pulmonary oedema—Prednisone—chronic obstructive pulmonary disease	0.000306	0.00426	CcSEcCtD
Naloxone—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000306	0.00425	CcSEcCtD
Naloxone—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000306	0.00425	CcSEcCtD
Naloxone—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000305	0.00425	CcSEcCtD
Naloxone—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000304	0.00423	CcSEcCtD
Naloxone—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000304	0.00423	CcSEcCtD
Naloxone—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000303	0.00421	CcSEcCtD
Naloxone—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000303	0.00421	CcSEcCtD
Naloxone—Hyperkinesia—Prednisone—chronic obstructive pulmonary disease	0.0003	0.00417	CcSEcCtD
Naloxone—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000299	0.00417	CcSEcCtD
Naloxone—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000296	0.00413	CcSEcCtD
Naloxone—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000288	0.00402	CcSEcCtD
Naloxone—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000287	0.004	CcSEcCtD
Naloxone—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000286	0.00398	CcSEcCtD
Naloxone—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000284	0.00396	CcSEcCtD
Naloxone—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00028	0.0039	CcSEcCtD
Naloxone—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000278	0.00387	CcSEcCtD
Naloxone—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000278	0.00387	CcSEcCtD
Naloxone—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000274	0.00381	CcSEcCtD
Naloxone—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000269	0.00374	CcSEcCtD
Naloxone—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000269	0.00374	CcSEcCtD
Naloxone—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000266	0.00371	CcSEcCtD
Naloxone—Pain—Formoterol—chronic obstructive pulmonary disease	0.000266	0.00371	CcSEcCtD
Naloxone—ESR1—respiratory system—chronic obstructive pulmonary disease	0.000265	0.0553	CbGeAlD
Naloxone—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000264	0.00368	CcSEcCtD
Naloxone—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000263	0.00367	CcSEcCtD
Naloxone—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000262	0.00365	CcSEcCtD
Naloxone—Pain—Montelukast—chronic obstructive pulmonary disease	0.000261	0.00363	CcSEcCtD
Naloxone—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.00026	0.00362	CcSEcCtD
Naloxone—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000254	0.00354	CcSEcCtD
Naloxone—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000252	0.0035	CcSEcCtD
Naloxone—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000246	0.00343	CcSEcCtD
Naloxone—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000246	0.00343	CcSEcCtD
Naloxone—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000246	0.00343	CcSEcCtD
Naloxone—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000246	0.00343	CcSEcCtD
Naloxone—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000245	0.00342	CcSEcCtD
Naloxone—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000243	0.00339	CcSEcCtD
Naloxone—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000241	0.00336	CcSEcCtD
Naloxone—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000241	0.00336	CcSEcCtD
Naloxone—Irritability—Prednisone—chronic obstructive pulmonary disease	0.000238	0.00331	CcSEcCtD
Naloxone—Cardiac arrest—Prednisone—chronic obstructive pulmonary disease	0.000237	0.0033	CcSEcCtD
Naloxone—ESR1—connective tissue—chronic obstructive pulmonary disease	0.000233	0.0487	CbGeAlD
Naloxone—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000233	0.00324	CcSEcCtD
Naloxone—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000233	0.00324	CcSEcCtD
Naloxone—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000229	0.00319	CcSEcCtD
Naloxone—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000224	0.00311	CcSEcCtD
Naloxone—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000224	0.00311	CcSEcCtD
Naloxone—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000219	0.00305	CcSEcCtD
Naloxone—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000213	0.00297	CcSEcCtD
Naloxone—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000213	0.00297	CcSEcCtD
Naloxone—ESR1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000213	0.0446	CbGeAlD
Naloxone—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000211	0.00294	CcSEcCtD
Naloxone—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000209	0.00291	CcSEcCtD
Naloxone—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000201	0.0028	CcSEcCtD
Naloxone—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000198	0.00276	CcSEcCtD
Naloxone—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000198	0.00276	CcSEcCtD
Naloxone—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000194	0.0027	CcSEcCtD
Naloxone—Depression—Prednisone—chronic obstructive pulmonary disease	0.000192	0.00267	CcSEcCtD
Naloxone—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000187	0.0026	CcSEcCtD
Naloxone—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000185	0.00258	CcSEcCtD
Naloxone—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000185	0.00258	CcSEcCtD
Naloxone—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000181	0.00252	CcSEcCtD
Naloxone—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000179	0.00249	CcSEcCtD
Naloxone—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000178	0.00248	CcSEcCtD
Naloxone—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000175	0.00243	CcSEcCtD
Naloxone—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.000172	0.00239	CcSEcCtD
Naloxone—SLCO1A2—lung—chronic obstructive pulmonary disease	0.000166	0.0346	CbGeAlD
Naloxone—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000165	0.00229	CcSEcCtD
Naloxone—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000163	0.00227	CcSEcCtD
Naloxone—Flushing—Prednisone—chronic obstructive pulmonary disease	0.00016	0.00223	CcSEcCtD
Naloxone—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000157	0.00218	CcSEcCtD
Naloxone—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000152	0.00211	CcSEcCtD
Naloxone—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000151	0.0021	CcSEcCtD
Naloxone—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000144	0.00201	CcSEcCtD
Naloxone—ESR1—lung—chronic obstructive pulmonary disease	0.00014	0.0294	CbGeAlD
Naloxone—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000138	0.00192	CcSEcCtD
Naloxone—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.00013	0.00181	CcSEcCtD
Naloxone—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.00013	0.00181	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000127	0.00177	CcSEcCtD
Naloxone—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.00012	0.00167	CcSEcCtD
Naloxone—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.00012	0.00167	CcSEcCtD
Naloxone—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000119	0.00166	CcSEcCtD
Naloxone—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000119	0.00165	CcSEcCtD
Naloxone—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.00011	0.00153	CcSEcCtD
Naloxone—ABCB1—respiratory system—chronic obstructive pulmonary disease	0.000105	0.0219	CbGeAlD
Naloxone—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.0001	0.0014	CcSEcCtD
Naloxone—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	9.69e-05	0.00135	CcSEcCtD
Naloxone—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	9.69e-05	0.00135	CcSEcCtD
Naloxone—Asthenia—Prednisone—chronic obstructive pulmonary disease	8.8e-05	0.00122	CcSEcCtD
Naloxone—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	8.39e-05	0.00117	CcSEcCtD
Naloxone—Vomiting—Prednisone—chronic obstructive pulmonary disease	7.8e-05	0.00109	CcSEcCtD
Naloxone—ABCB1—trachea—chronic obstructive pulmonary disease	7.72e-05	0.0162	CbGeAlD
Naloxone—Nausea—Prednisone—chronic obstructive pulmonary disease	7.28e-05	0.00101	CcSEcCtD
Naloxone—ABCB1—lung—chronic obstructive pulmonary disease	5.55e-05	0.0116	CbGeAlD
Naloxone—CREB1—Axon guidance—EGFR—chronic obstructive pulmonary disease	2.06e-05	0.000211	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	2.06e-05	0.000211	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.05e-05	0.00021	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.03e-05	0.000207	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.02e-05	0.000206	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.02e-05	0.000206	CbGpPWpGaD
Naloxone—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	1.99e-05	0.000203	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	1.96e-05	0.000201	CbGpPWpGaD
Naloxone—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	1.96e-05	0.000201	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.93e-05	0.000197	CbGpPWpGaD
Naloxone—OPRK1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.93e-05	0.000197	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	1.91e-05	0.000195	CbGpPWpGaD
Naloxone—ESR1—Signaling by ERBB4—IL6—chronic obstructive pulmonary disease	1.9e-05	0.000194	CbGpPWpGaD
Naloxone—ALB—Hemostasis—HDAC2—chronic obstructive pulmonary disease	1.89e-05	0.000193	CbGpPWpGaD
Naloxone—CREB1—Immune System—CD8A—chronic obstructive pulmonary disease	1.87e-05	0.000191	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.86e-05	0.00019	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.85e-05	0.000189	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.84e-05	0.000188	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	1.84e-05	0.000188	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.84e-05	0.000187	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.83e-05	0.000187	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.83e-05	0.000187	CbGpPWpGaD
Naloxone—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	1.83e-05	0.000187	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—MMP9—chronic obstructive pulmonary disease	1.82e-05	0.000186	CbGpPWpGaD
Naloxone—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	1.8e-05	0.000184	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	1.8e-05	0.000184	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—SERPINE1—chronic obstructive pulmonary disease	1.79e-05	0.000183	CbGpPWpGaD
Naloxone—ALB—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	1.78e-05	0.000182	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.77e-05	0.00018	CbGpPWpGaD
Naloxone—CREB1—Signaling by NGF—IL6—chronic obstructive pulmonary disease	1.75e-05	0.000179	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—CTGF—chronic obstructive pulmonary disease	1.75e-05	0.000179	CbGpPWpGaD
Naloxone—CREB1—Immune System—ERBB3—chronic obstructive pulmonary disease	1.74e-05	0.000178	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.73e-05	0.000177	CbGpPWpGaD
Naloxone—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	1.73e-05	0.000177	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	1.73e-05	0.000177	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.72e-05	0.000176	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.72e-05	0.000175	CbGpPWpGaD
Naloxone—ALB—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.71e-05	0.000175	CbGpPWpGaD
Naloxone—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	1.71e-05	0.000175	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.71e-05	0.000174	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.71e-05	0.000174	CbGpPWpGaD
Naloxone—ALB—Hemostasis—PLAUR—chronic obstructive pulmonary disease	1.7e-05	0.000174	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.7e-05	0.000173	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	1.68e-05	0.000172	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GC—chronic obstructive pulmonary disease	1.68e-05	0.000171	CbGpPWpGaD
Naloxone—TLR4—Immune System—IL6—chronic obstructive pulmonary disease	1.67e-05	0.00017	CbGpPWpGaD
Naloxone—ALB—Metabolism—GC—chronic obstructive pulmonary disease	1.67e-05	0.00017	CbGpPWpGaD
Naloxone—ESR1—Generic Transcription Pathway—SERPINE1—chronic obstructive pulmonary disease	1.66e-05	0.000169	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	1.64e-05	0.000167	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.63e-05	0.000167	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.63e-05	0.000167	CbGpPWpGaD
Naloxone—SLCO1A2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.63e-05	0.000167	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—HDAC2—chronic obstructive pulmonary disease	1.63e-05	0.000166	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.62e-05	0.000165	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.61e-05	0.000165	CbGpPWpGaD
Naloxone—CREB1—Disease—ERBB3—chronic obstructive pulmonary disease	1.61e-05	0.000164	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.6e-05	0.000164	CbGpPWpGaD
Naloxone—CREB1—Immune System—CRP—chronic obstructive pulmonary disease	1.59e-05	0.000163	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—IL6—chronic obstructive pulmonary disease	1.59e-05	0.000162	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.56e-05	0.000159	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.55e-05	0.000158	CbGpPWpGaD
Naloxone—ALB—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.55e-05	0.000158	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.55e-05	0.000158	CbGpPWpGaD
Naloxone—CREB1—Immune System—TLR4—chronic obstructive pulmonary disease	1.53e-05	0.000156	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.5e-05	0.000154	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	1.5e-05	0.000153	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.5e-05	0.000153	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.5e-05	0.000153	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.49e-05	0.000153	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—EGFR—chronic obstructive pulmonary disease	1.47e-05	0.00015	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	1.46e-05	0.000149	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.45e-05	0.000148	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.41e-05	0.000144	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—TNF—chronic obstructive pulmonary disease	1.4e-05	0.000143	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	1.4e-05	0.000142	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.39e-05	0.000142	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.38e-05	0.000141	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.36e-05	0.000139	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.36e-05	0.000138	CbGpPWpGaD
Naloxone—CREB1—Disease—NOS2—chronic obstructive pulmonary disease	1.34e-05	0.000137	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	1.33e-05	0.000136	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.31e-05	0.000134	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—EGFR—chronic obstructive pulmonary disease	1.3e-05	0.000133	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.29e-05	0.000132	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.27e-05	0.00013	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—EGFR—chronic obstructive pulmonary disease	1.25e-05	0.000128	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.25e-05	0.000127	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.24e-05	0.000127	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.24e-05	0.000127	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.24e-05	0.000126	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.23e-05	0.000126	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	1.23e-05	0.000126	CbGpPWpGaD
Naloxone—ALB—Hemostasis—MMP1—chronic obstructive pulmonary disease	1.22e-05	0.000124	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	1.21e-05	0.000124	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.21e-05	0.000124	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.19e-05	0.000122	CbGpPWpGaD
Naloxone—ALB—Hemostasis—PLAU—chronic obstructive pulmonary disease	1.19e-05	0.000122	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.19e-05	0.000121	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	1.16e-05	0.000119	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.13e-05	0.000116	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—IL6—chronic obstructive pulmonary disease	1.13e-05	0.000116	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.13e-05	0.000115	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	1.13e-05	0.000115	CbGpPWpGaD
Naloxone—CREB1—Disease—SERPINE1—chronic obstructive pulmonary disease	1.13e-05	0.000115	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.13e-05	0.000115	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.12e-05	0.000115	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.12e-05	0.000115	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	1.11e-05	0.000114	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.11e-05	0.000113	CbGpPWpGaD
Naloxone—ALB—Hemostasis—NOS2—chronic obstructive pulmonary disease	1.1e-05	0.000112	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.09e-05	0.000111	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	1.09e-05	0.000111	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.08e-05	0.000111	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.08e-05	0.000111	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.08e-05	0.00011	CbGpPWpGaD
Naloxone—CREB1—Disease—NOS3—chronic obstructive pulmonary disease	1.08e-05	0.00011	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.06e-05	0.000108	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	1.04e-05	0.000106	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.02e-05	0.000105	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.01e-05	0.000103	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.01e-05	0.000103	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—IL6—chronic obstructive pulmonary disease	9.99e-06	0.000102	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL1B—chronic obstructive pulmonary disease	9.94e-06	0.000102	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	9.91e-06	0.000101	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.85e-06	0.000101	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KL—chronic obstructive pulmonary disease	9.85e-06	0.000101	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	9.48e-06	9.68e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	9.24e-06	9.44e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	9.23e-06	9.43e-05	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	9.23e-06	9.42e-05	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	9.16e-06	9.36e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	9.16e-06	9.35e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.15e-06	9.35e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.1e-06	9.29e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	9.09e-06	9.28e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GCLC—chronic obstructive pulmonary disease	9.05e-06	9.24e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GCLC—chronic obstructive pulmonary disease	9e-06	9.19e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	8.99e-06	9.18e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.81e-06	9e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—NOS3—chronic obstructive pulmonary disease	8.81e-06	9e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	8.44e-06	8.61e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	8.38e-06	8.56e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	8.36e-06	8.54e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	8.32e-06	8.5e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	8.29e-06	8.47e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	8.26e-06	8.44e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CTGF—chronic obstructive pulmonary disease	8.26e-06	8.43e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CTGF—chronic obstructive pulmonary disease	8.21e-06	8.38e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	8.12e-06	8.29e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	8.01e-06	8.18e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.97e-06	8.14e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—SERPINE1—chronic obstructive pulmonary disease	7.97e-06	8.14e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.91e-06	8.08e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.89e-06	8.05e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	7.88e-06	8.05e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—ALB—chronic obstructive pulmonary disease	7.65e-06	7.81e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.61e-06	7.77e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—EGFR—chronic obstructive pulmonary disease	7.57e-06	7.73e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.56e-06	7.72e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.55e-06	7.71e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.53e-06	7.69e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	7.45e-06	7.61e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	7.38e-06	7.54e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	7.31e-06	7.47e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	7.25e-06	7.4e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	7.19e-06	7.34e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—TGFB1—chronic obstructive pulmonary disease	7.13e-06	7.28e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	7.1e-06	7.25e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—EGFR—chronic obstructive pulmonary disease	6.99e-06	7.14e-05	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	6.99e-06	7.14e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.92e-06	7.06e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.7e-06	6.84e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.68e-06	6.82e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.63e-06	6.77e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	6.6e-06	6.74e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.6e-06	6.74e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	6.37e-06	6.51e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	6.35e-06	6.49e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—VEGFA—chronic obstructive pulmonary disease	6.35e-06	6.48e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.34e-06	6.48e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.31e-06	6.44e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.26e-06	6.39e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.22e-06	6.35e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	6.12e-06	6.25e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.06e-06	6.19e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.04e-06	6.17e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.86e-06	5.98e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	5.84e-06	5.97e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.83e-06	5.95e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—TGFB1—chronic obstructive pulmonary disease	5.83e-06	5.95e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL6—chronic obstructive pulmonary disease	5.82e-06	5.94e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.8e-06	5.92e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.58e-06	5.7e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.57e-06	5.69e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.53e-06	5.64e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.53e-06	5.64e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.5e-06	5.61e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.45e-06	5.57e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.44e-06	5.56e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.42e-06	5.54e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—IL6—chronic obstructive pulmonary disease	5.37e-06	5.49e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.3e-06	5.41e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	5.18e-06	5.29e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.08e-06	5.19e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.99e-06	5.1e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.98e-06	5.08e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.95e-06	5.05e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.95e-06	5.05e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.91e-06	5.02e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.9e-06	5e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.88e-06	4.98e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	4.86e-06	4.96e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.81e-06	4.92e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—TP53—chronic obstructive pulmonary disease	4.8e-06	4.9e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.76e-06	4.86e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.71e-06	4.81e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.48e-06	4.57e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	4.43e-06	4.52e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.39e-06	4.48e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.37e-06	4.46e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.28e-06	4.37e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.11e-06	4.2e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.1e-06	4.19e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.08e-06	4.17e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.02e-06	4.1e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.97e-06	4.05e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.76e-06	3.84e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ALB—chronic obstructive pulmonary disease	3.76e-06	3.84e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.75e-06	3.83e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.69e-06	3.77e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.62e-06	3.69e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.59e-06	3.67e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—NOS3—chronic obstructive pulmonary disease	3.59e-06	3.67e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—NOS3—chronic obstructive pulmonary disease	3.57e-06	3.65e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.56e-06	3.64e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.41e-06	3.48e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.36e-06	3.43e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.29e-06	3.36e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	3.27e-06	3.34e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.27e-06	3.34e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.21e-06	3.28e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	3.13e-06	3.2e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.13e-06	3.2e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.04e-06	3.1e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.97e-06	3.03e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.78e-06	2.84e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.69e-06	2.75e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.47e-06	2.52e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	2.02e-06	2.06e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	1.93e-06	1.97e-05	CbGpPWpGaD
